Lumos FebriDx Sites Climb As Product Sales Surge, Despite Lower Quarterly Revenue
Closing price · 2026-10-27: $0.064 · -23.81%
Lumos Diagnostics said FebriDx was being actively ordered and used at 265 US healthcare sites, up from 215 in mid-September and 170 in late July, while evaluations expanded to 485 sites from 405. Quarterly revenue fell 39% year on year to about US$2 million, but product revenue rose 224% and FebriDx sales increased 351%; the prior-year quarter included a one-off exclusivity fee. The company ended the quarter debt-free with approximately US$12 million in cash, while its paediatric study has enrolled fewer patients and bacterial-positive cases than planned.